UNITED STATES SECURITIES EXCHANGE COMMISSION
                         WASHINGTON, D.C.  20549

                              FORM 10-KSB

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                       FOR FISCAL YEAR ENDED:  September 30, 2004

                       COMMISSION FILE NO.:   000-49955

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                       FOR THE TRANSITION PERIOD FROM _____ TO _____

                         CIMBIX  CORPORATION
          -------------------------------------------------
           (Name of small business issuer in its charter)

            Washington                            91-2060082
-----------------------------------    -----------------------------
(State or other jurisdiction of              (I.R.S. Employer
 incorporation or organization)               Identification No.)

#112, 5414 Cameron Street
Las Vegas, Nevada                               89118
-----------------------------------------    -----------------------
(Address of principle executive offices)        ( Zip Code)

Issuer's telephone number:  (415) 924-9164
                            -----------------------

Securities registered under Section 12(b) of the Exchange Act:  None
Securities registered under Section 12(g) of the Exchange Act:

         Common Stock, $0.0001 par value
         ------------------------------------
          (Title of Class)

Check whether the issuer (1) filed all reports required to be filed
By Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.            YES [x]    NO [ ]

Check if disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will
be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III
of this Form 10-KSB or any amendment to this Form 10-KSB.   [ ]

Issuer's revenues for its most recent fiscal year was $ NIL

The aggregate market value of the voting common stock held by non-
affiliates of the Registrant as of September 30, 2004 was approximately
$102,800 dollars.

State the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date:

42,967,100 SHARES OF $0.0001 PAR VALUE COMMON STOCK
OUTSTANDING AS OF SEPTEMBER 30, 2004.

Transitional Small Business Disclosure Format (check one):
                                                    Yes [ ] No [ x ]

<PAGE>

PART 1

Certain statements contained in this Form 10-KSB constitute "forward-
looking statements" within the meaning of Section 27A of the
Securities Act of 1933,as amended (the "Securities Act"), and Section
21E of the Exchange Act. These statements, identified by words such
as "plan", "anticipate," "believe," "estimate," "should," "expect"
and similar expressions, include our expectations and objectives
regarding our future financial position, operating results and
business strategy. These statements reflect the current views of
management with respect to future events and are subject to risks,
uncertainties and other factors that may cause our actual results,
performance or achievements, or industry results, to be materially
different from those described in the forward-looking statements.
Such risks and uncertainties include those set forth under the
captions "Description of Business", "Management's Discussion and
Analysis or Plan of Operation" and elsewhere in this Form 10-KSB. We
do not intend to update the forward-looking information to reflect
actual results or changes in the factors affecting such forward-
looking information.

ITEM 1.  DESCRIPTION OF BUSINESS

GENERAL

The Company was incorporated under the laws of the State of
Washington on August 17, 2000 and has been a reporting issuer with
the United States Securities and Exchange Commission since November
2000.  On August 26, 2003, the Company changed its name from
Corporate Development and Innovation, Inc. to Cimbix Corporation
("Cimbix", the "Company").  Cimbix received approval from its filing
with the NASD and began trading on the OTC Bulletin Board January
2004 under the symbol "CMBX".  As part of its restructuring and
reorganization plans, a reverse split was effected on October 8,
2004.  The Company now trades under the ticker symbol, "CBXC".

The Company's business is still in its early developmental and
promotional stages and to date, the Company's primary activities
have involved significant re-structuring and re-organization;
completion of private placements; resolving issues and challenges
created by prior management relating to the share exchange
agreement with Millennium Business Group (USA) Inc. ("MBG USA");
and the creation of another wholly owned subsidiary, Advanced Dental
Technologies Inc. ("ADT")

Since the Company's inception and up until approximately March of
2003, the Company was engaged solely in the market development and
sale of vitamins, minerals, nutritional supplements, and other health
and fitness products over the internet.  The Company's limited focus
was the result of an exclusive license agreement with
Vitamineralherb.com to market, distribute and sell their
Vitamineralherb.com products to health and fitness professionals in
the state of Illinois less the counties of Jo Davies, Stevenson,
Winnebago, Rock Island, Henry, Will, Kankakee, Iroquois and
Vermillion.  The three year license agreement with
Vitamineralherb.com expired and the Company made no plans to renew.

On March 24, 2003, the Company acquired 100% of the shares of MBG
USA making it a wholly owned subsidiary.  Our plan was to compliment,
augment and extend the early stage activities and business plans of
the Company.

On or around the beginning of 2004, the Company learned of some
unresolved issues relating to certain shareholders of MBG USA, and
issues relating to certain assets of MBG USA as well as accounting
concerns subsequent to the closing of the share exchange agreement
with MBG USA.  As a result of these activities, the Company was
not able to undertake the development and the creation
of the additional business segments.

In February 2004, the Company incorporated a wholly owned
subsidiary in the State of Nevada named Advanced Dental Technologies
Inc. ("ADT") and have transferred all the intellectual property
from MBG USA to ADT. Originally, the wholly owned subsidiary
of the Company, MBG USA was to form the Company's intellectual
property and technology transfer division.  The strong intellectual
property position was based on four validly issued and assigned U.S.
Patents [all in the area of dental implant abutment components,
devices and techniques]. It is the Company's intention over the next
year, to develop and implement a legal strategy to help extract
financial compensation from certain entities which have chosen to
wilfully infringe on the Company's patents by commercializing
similar technologies. The MBG USA entity has already been able to
effectuate and finalize a U.S. court directed legal settlement with
one infringing company (dated and executed on June 26, 2002) which
resulted in a fully paid up license fee and cash settlement of
$280,000 USD.

Management has started the registration of the four patents in
Canada and the United Kingdom and is starting to further evaluate,
develop, manage and fund the commercialization, sub-license and or
commercial sale of these various assets.  Our ability to continue
with the business plan is contingent upon our obtaining additional
capital to assist in developing the concept and the new operational
plan.  We are also actively investigating other business
opportunities to accentuate our current business.

BUSINESS

Our patents are in the field of cosmetic dentistry known as
osseointegrated implant therapy.  Dental implantology, also known
as oral implantology, has been in practice for some twenty years
and is considered to be a fairly new area of dentistry and
considered as a viable alternative to fixed and removable prosthetic
restorations.   Conventional methods for replacing missing tooth or
teeth and gaps have always been dentures and bridges.  Dental
implantology is an alternative method for replacing missing tooth
or teeth or gaps. The difference between the conventional methods
and dental implants is that implants are permanently anchored into
the jaw.  Implants will look and feel as good as your own teeth.

A dental implant is an artificial tooth with a metallic root that
is placed in the bone of the jaw to hold a replacement tooth or
bridge.  The implant is made out of titanium, a metal that is
tolerated by the human body with little resistance and side effects.
There are three types of dental implants.  The most common type is
known as "endosteal" or "endosseous" which means "in the bone".
These include screws, cylinders or blades that are surgically
placed into the jaw bone.  Each implant can hold one or more
prosthetic teeth.  This type of implant is usually used as an
option for patients with bridges or removable dentures.  The other
type of dental implant is known as "eposteal" or "subperiosteal"
which means "on the bone". With this type, the device is placed
on top of the jaw with metal framework posts that protrudes through
the gum to hold the prosthesis.  This form of implant is usually
used as an option for patients that are unable to wear conventional
dentures or bridges, and for those who have minimal bone height.
The last type of dental implant is known as "transosteal" or
"transosseous" which means "through the bone".  The device
with threaded posts from the bone plate of the jaw goes through
the bone to provide support and attachment for the dental
prosthesis.  This type of implant is used when the jaws are
deformed resulting from trauma, tumors or injuries.

There are many advantages with this new revolutionary discovery
of implantology.  One of the most prominent features is that the
implants do not have to rely on neighboring teeth for support like
conventional methods of dentures and bridges.  Therefore, the
implant abutments do not have to be adjusted or re-adjusted due to
progressive loss of the supporting and neighboring teeth or other
problems relating to tissues and gums. They look and feel natural
like your own teeth.

Our dental implant abutment assembly, process and designs, which
we have patented, are based on extensive dental research, analysis
and clinical studies.  The patents provide universal usage that
does not require a central bore in the core component for insertion
of the implant screw.  This distinct feature provides an open
palate for fashioning wax-ups and casting abutments to match the
natural tooth shape it replaces and at any positions.  The
universal abutment technology we have, permits unlimited vertical
and horizontal positioning which can eliminate compromise of
fixation screw, base or abutment strength caused by grinding or
heating in other designs.  This system may be easily disassembled
and retrieved with no requirement for dental adhesive.  With this
flexibility, it allows a better alternative method for replacing
teeth and/or other dental restorative devices.

The abutment systems we designed also allow other attachment
components to be placed in the abutment which can hold other
corresponding components fixed in the interior segment of a bridge,
denture or other prosthesis so the prosthesis can easily be removed
to be cleaned.  These systems, devices and techniques are
appropriate for any removable bridges, overdentures, other
prosthesis and implant-based dental restorative devices.

MARKET ANALYSIS

In the US, about eleven percent of the population is missing all
Their teeth and about thirty-five percent are missing some teeth.
Dental implants are a viable alternative to dental bridges or
Dentures commonly used to resolve the problems of missing teeth.
The dental implant market is estimated to be about one billion
dollars worldwide and is growing at approximately eighteen percent
per year.  There are about five major companies that control about
eighty-five percent of the market.

Our subsidiary, MBG USA settled a patent infringement action with
one of those companies, the Swiss company called Strauman.  Cimbix
through its subsidiary ADT, will be investigating whether any other
company has infringed on the patents as well as licensing and/or
the production of dental implants based on the patents.  There are
several companies that are of interest either as to the issue of
patent infringement and/or licensing production.

Some attributes to this fast growing industry can be related to major
developments of this new technology which minimizes side effects and
complications that would normally be associated with dentures,
bridges and other restorative devices; this new technology which
is more efficient; this new technology which does not rely on
neighboring teeth for support; this new technology which provides
natural looking teeth and this new technology provides people with
greater confidence and better oral hygiene.

We believe that there exist a significant market opportunity for
Our dental implant abutment systems.  Our technology has a great
impact in osseointegrated implant therapy.  There are no hassles
and problems and minimal side effects, if any. The systems are
flexible, easy to install and to clean. The implants are
cosmetically more attractive and makes your teeth feel and look
natural.  Dental implantology has been proven to satisfy the
dental implant markets as it extends to all dental companies that
manufactures, if not, promote alternative replacement to dentures
and bridges. Many universities, colleges, foundations, private
companies and laboratories unknown to us are researching new
dental implant abutment systems everyday. We believe that the
existing conventional methods of replacing teeth are ineffective
and believe that dental implant therapy will become the method
of choice for teeth replacement.

Studies have show that dental implant systems have shown success
rates of greater than ninety per cent.  Adverse effects on
implants have been attributed to uncontrolled diabetes, alcoholism,
heavy smoking, post-irradiated jaws and poor oral hygiene. However,
individuals with a strong susceptibility to periodontitis can be
treated successfully with implants.  Age is not an important factor
that affects implant survival, but is considered important in
treatment planning.  For example, when implants are placed in
adolescent, it has been recommended that they be monitored closely
and restored with a prosthesis designed for adaptation to a
developing jaw. Prospective patients should be emotionally stable,
cooperative and willing to keep the appointments required for
completion of treatment and maintenance. Restorative requirements
such as space and jaw relationships, location of edentulous areas,
quantity and quality of available bone should be evaluated before
implants are selected as a treatment option. The success rates of
dental implants depend on the bone quality and bone volume. If
bone quality and quantity are inadequate, then bone augmentation
procedures may be indicated.

We believe that dental implants have revolutionized the fields of
implants and periodontics. During the last decades, there have
been a great deal of information generated concerning the
effectiveness and predictability of dental implant systems.  We
believe that implant abutment systems like ours is a viable
option in the treatment of partial and full teeth replacement
therapy.  The available abutment systems are successful.

DEVELOPMENTS AND CONTEMPLATED ACTIVITIES

We currently have minimal cash reserves and a significant working
capital deficit.   Accordingly, our ability to pursue our plan of
operations is contingent on our being able to obtain funding for the
development and commercialization of our products and services.  We
commenced an offering in the form of equity financing from the sale
of our common stock in the principal amount of up to $90,000 to
persons who are "accredited investors" in private placement
transactions.  There is no assurance we will be able to raise any
funds through this offering.


SUBSIDIARIES

We entered into a share exchange agreement with the shareholders of
Millennium Business Group (USA) ("MBG USA") in March 2003.
The acquisition of MBG USA makes it a wholly owned subsidiary of
the Company.  The acquisition of MBG USA was to further accentuate
the Company's focus on medical technologies.

As part of the restructuring and reorganization of the Company, the
Company incorporated Advanced Dental Technologies Inc. ("ADT")
in the State of Nevada as another wholly owned subsidiary of the
Company in February 2004.  The four dental patents of MBG USA were
transferred into ADT so the Company can better protect and finance
development of the patents.

PATENTS AND TRADEMARKS

We will attempt to protect the patents and proprietary technologies
held by our subsidiary, ADT, in as many countries in the world as
economically feasible.  The patent position of dental device firms,
including our company, generally is highly uncertain and may involve
complex legal and factual questions.  Potential competitors may have
filed applications for, or may have been issued patents, or may
obtain additional patents and proprietary rights relating to products
or processes in the same area of technology as that used by our
Company. The scope and validity of these patents and applications,
the extent to which we may be required to obtain licenses thereunder
or under other proprietary rights, and the cost and availability of
licenses are uncertain.

We will require our employees, consultants, advisers, and suppliers
to execute a confidentiality agreement upon the commencement of an
employment, and or consulting relationship with us. The agreement
provides that all confidential information developed by or made
known to the individual during the course of the relationship will
be kept confidential and not disclosed to third parties except in
specified circumstances. In the case of employees, the agreements
provide that all inventions conceived by the individual will be the
exclusive property of our company. We cannot assure you, however,
that these agreements will provide meaningful protection for our
trade secrets in the event of an unauthorized use or disclosure of
such information.

RESEARCH AND DEVELOPMENT EXPENDITURES

The Company entered into a share exchange agreement with MBG
USA issuing a total of 4,018,000 shares of its common stock, 500,000
shares of its preferred stock and 1,938,000 warrants so that MBG USA
becomes a wholly owned subsidiary of the Company.  Through our
internal investigations, the previous management of the Company did
not appropriately establish the voting preferred shares of the
Company. On May 30, 2004, the Company filed a Certificate of
Designation to establish the designations, preferences, limitations
and relative rights of the preferred shares of Series A.  Each
outstanding Series A Preferred Stock is entitled to one (1) vote. At
year end September 30, 2004, there was an outstanding 500,000
preferred shares of Series A which was issued according to the share
exchange agreement with MBG USA,  with each preferred share holding
only one (1) vote each.  The preferred stock issued to the
shareholders of MBG USA, is not convertible.

We have plans to focus on our research and development activities to
verify the viability and marketability underlying our patents this
fiscal year.  Substantial research and development efforts are
required to be completed in order to determine the viability of the
patents so the Company maybe able to negotiate licenses to generate
revenue commercially.  We can not estimate the time required to
complete these activities.  We cannot assure that we will ever develop
a product that is approved for commercial distribution.

COMPETITION

We cannot assure you that any of our patents
will afford protection against competitors with similar technology;
nor can we assure you that any of our patents will not be designed
around by others or that others will not obtain patents that we
would need to license or design around.

Management plans, as soon as time and finances permit, to hire
management advisors for its US based operations especially in the
areas of finance, sales, marketing and investor/public relations.
Cimbix may also choose to outsource some of its marketing roles by
utilizing a series of independent contractors based on the projected
size of the market and the compensation necessary to retain qualified
employees.

ITEM 2.  DESCRIPTION OF PROPERTY

Cimbix's Head offices are located at #112, 5415 Cameron Street,
Las Vegas, Nevada 89118.  The Company's phone number is
415-924-9164.

The Company maintains a business office in Vancouver, B.C., Canada as
well as an office in Larkspur, California which is maintained by Mr.
Donald Walker, the Company's director and President.  The Canadian
offices are located at Suite 733, 141-6200 McKay Avenue, Burnaby,
British Columbia, Canada V5H 4H9. The U.S. offices are located at
Suite 112, 5415 Cameron Street, Las Vegas, Nevada 89118. The
telephone number is 415-924-9164.

Additionally, Mr. Robert Rosner, MBG USA's Vice President of Investor
Relations and Business Development as well as the Company's Vice
President of Regulatory Affairs and Compliance officer and Corporate
Secretary, maintains an office on behalf of all three Companies in
the greater Los Angeles, California area. The U.S. investor relations,
sales office and corporate compliance offices are located at Suite
134, 9663 Santa Monica Boulevard, Beverly Hills, California 90210. The
telephone number is 310-435-0435.

ITEM 3.  LEGAL PROCEEDINGS

To the knowledge of the board of directors of Cimbix, the Company is
not currently party to any legal proceeding or litigation.

During the fiscal year, the Company resolved some ongoing issues and
challenges created by prior management relating to the share exchange
agreement with MBG USA. The Company also settled matters with the
former sole director and officer of the Company, Edwin Lao.

ITEM 4.  SUBMISSION OF MATTER TO A VOTE OF SECURITY HOLDERS

On September 23, 2004, a majority of shareholders of the Company, via
signed written consent to action without a meeting of the shareholders,
approved a 200:1 reverse stock split.  The number of pre-split shares
consenting to the action was 37,825,000 out of 42,967,100 pre-split
shares that were eligible to vote.  The 37,825,000 pre-split shares
eligible to vote does not include the 500,000 pre-split shares of
Series A Preferred Stock vote which vote was 500,000 pre-split shares.

PART II

ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED
               SHAREHOLDER MATTERS

"Bid" and "asked" offers for the common stock are listed on the NASD
OTC-Bulletin Board published by the National Quotation Bureau, Inc.
The trading symbol for the common stock was "CMBX" and was changed
to "CBXC" in connection with the Company's reverse stock split in
October 2004.  Prior to January 2004, there was no trading market for
the Company's common stock.

The following table sets forth the high and low bid prices for the
Company's  common  stock  for  the  periods  indicated as reported by
the NASD OTC-Bulletin  Board.  The quotations reflect inter-dealer
prices, without retail mark-up, mark-down or commission and may not
represent actual transactions.

<TABLE>
<CAPTION>


                                      Bid Prices
Quarter Ended                      High      Low
------------------                 -----    -----
<S>                               <C>       <C>

September 30, 2004                  0.60     0.02
June 30, 2004                       0.60     0.40
March 31, 2004                      0.00     0.00
December 31, 2003                   0.00     0.00

</TABLE>

There were 94 holders of record of the common stock as of January 24,
2005.  The Company has never paid a cash dividend on its common stock
and does not anticipate the payment of a cash dividend in the
foreseeable future. The Company intends to reinvest in its business
operations any funds that could be used to pay a cash dividend. The
Company's common stock is considered a "penny stock" as defined in
certain rules (the  "Rules") under the Securities Exchange Act of
1934. In general, a security which is not quoted on NASD or has a
market price of less than $5 per share where the issuer does not
have in excess of $2,000,000 in net tangible assets (none of which
conditions the Company meets) is considered a penny stock.  The SEC's
rules regarding penny stocks impose additional sales practice
requirements on broker-dealers who sell such securities to persons
other than established customers and accredited investors (generally
persons with net worth in excess of $1,000,000 or an annual income
exceeding $200,000 or $300,000 jointly with their spouse). For
transactions covered by the rules, the broker-dealer must make a
special suitability determination for the purchaser and receive the
purchaser's written agreement to the transaction prior to the sale.
Thus the Rules affect the ability of broker-dealers to sell the
Company's shares should they wish to do so because of the adverse
effect that the Rules have upon liquidity of penny stocks. Unless
the transaction is exempt under the Rules, under the Securities
Enforcement Remedies and Penny Stock Reform Act of 1990, broker-
dealers effecting customer transactions in penny stocks are required
to provide their customers with (i) a risk disclosure document; (ii)
disclosure of current bid and ask quotations if any; (iii) disclosure
of the compensation of the broker-dealer and its sales personnel in the
transaction; and (iv) monthly account statements showing the market
value of each penny stock held in the customer's account. As a result
of the penny stock rules the market liquidity for the Company's
securities may be severely adversely affected by limiting the ability
of broker-dealers to sell the Company's securities and the ability of
purchasers of the securities to resell them.

To date the Company has not paid any dividends on its common stock
and does not expect to declare or pay any dividends on its common
stock in the foreseeable future. Payment of any dividends will
depend upon the Company's future earnings, if any, its financial
condition, and other factors as deemed relevant by the Board of
Directors.

RECENT SALES OF UNREGISTERED SECURITIES

In June 2004, the Company issued 30,000,000 shares of its common
stock, $.0001 par value per share which were not registered under
the Act in consideration for $30,000 pursuant to a private
placement.  Donald Walker and Robert Rosner each subscribed to
15,000,000 shares.  The Company claims an exemption from
registration pursuant to Section 4(2) of the Act.

In October 2003, the Company issued 250,000 shares of its common
stock, $.0001 par value per share which were not registered under
the Act in consideration for $50,000 to the Robert Rosner pursuant
to a private placement.  The Company claims an exemption from
registration pursuant to Section 4(2) of the Act.

ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion of the financial condition and results of
operations of the Company should be read in conjunction with the
financial statements and the related notes thereto included elsewhere
in this annual report for the year ended September 30, 2004. This
annual report contains certain forward-looking statements and the
Company's future operating results could differ materially from those
discussed herein. Certain statements contained in this Report,
including, without limitation, statements containing the words
"believes," "anticipates," "expects" and the like, constitute
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-
looking statements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The
Company disclaims any obligation to update any such factors or to
announce publicly the results of any revisions of the forward-looking
statements contained or incorporated by reference herein to reflect
future events or developments.

STATUS OF OPERATIONS

During the period up to September 30, 2004, the Company has engaged
mainly in the restructuring and re-organization of the Company,
raising of operating capital, as well as the creation of another
wholly owned subsidiary, Advanced Dental Technologies Inc. ("ADT").

For the current fiscal quarter, the Company anticipates incurring a
loss as a result of organizational expenses and expenses associated
with setting up a company structure to resolve challenges from prior
management and to begin implementing its new operational plan. The
Company anticipates that until these procedures are completed, it
may not generate revenues, and may continue to operate at a loss
thereafter, depending upon the performance of the business.

LIQUIDITY AND CAPITAL RESOURCES

The Company remains in the development stage and since inception,
has experienced no significant change in liquidity or capital
resources or shareholders' equity.  The directors have advanced
funds into the Company to cover cash flow deficiencies.  The
advances have no stated repayment terms.  These funds were used to
pay legal and accounting expenses along with several other
miscellaneous operational infrastructure costs.

In the process of carrying out its business plan, the Company may
determine that it cannot raise sufficient capital to support any of
its business divisions on acceptable terms, or at all. The Company's
board of directors has a fiduciary duty to act in the best interests
of the corporation and its shareholders. The board of directors may
decide that it is in the best interests of the corporation and its
shareholders to liquidate the business, enter into a new line of
business or engage in a business combination with another business.

The Company is not currently a party to any contracts, letters of
intent, commitments or agreements and is not currently engaged in
active negotiations with respect to any acquisitions other than
those which have been otherwise described on its current websites.
Although the Company does not presently intend to enter into a new
line of business or business combination, it reserves the right to
change its mind in an attempt to either complement or accentuate
its current business initiatives.

The Company's financial statements are presented on a going concern
basis which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business.  At September 30,
2004 we have been unsuccessful in our efforts to raise additional
capital to meet our plan of operations. Our cash position as of
September 30, 2004 was $125. Since inception, we have recognized no
significant revenue.  We have accumulated operating losses of $592,405
and as of September 30, 2004 we had a working a capital deficiency of
$256,285.  At the present time, and over the next twelve months, our
primary focus will be to develop our new initiatives and operational
plan, to establish sales and to explore various methods for raising
additional funds.


PLAN OF OPERATION

We anticipate entering into agreements within the next twelve months
to hire consultants to address the viability, research, development
and market of our dental abutment patents.  Our objective is to
exploit our technology through product development for sales and
licensing of our patents to earn royalty revenue streams.

To achieve our new operational plan for the next 12 months, we will
need to raise substantial additional capital for our operations
through the sale of equity securities.  We have no cash to fund our
operations at this time, so we plan to offer common stock in a private
placement during the first quarter of 2005 to raise minimum proceeds
of $90,000.  We believe the proceeds from such a private placement
will enable us to fund expanded operations.

We also anticipate hiring a minimum of five consultants during the
next twelve months to enable us to continue research and development
of our technology, perform suitability testing for dental devices,
and pursue license opportunities with potential strategic partners.

The Company believes that in additional to its anticipated cash flows
from operations it will need at least an additional minimum $250,000
in further private placement funding in order to fulfill its business
plan. Accordingly, there can be no assurance that any additional funds
will be available on terms acceptable to the Company or at all.

If we are able to raise the additional funding of $250,000 in private
placement transactions over the next twelve months to cover our
minimum cash requirements to persons who are "accredited investors",
it would be allocated as follows:

$100,000 to hire additional managers and staff in the sales,
         marketing, web development and investor relations
         departments for our US offices.
$100,000 to spend on research and development and viability of
         of our patents.
$ 20,000 for outsourced advertising, graphic artwork and printing of
         marketing materials.
$ 30,000 for operational infrastructure costs including rent,
         communications, consumable supplies and travel.

We are presently in the early stages of development and promotional
stages of our business and we can provide no assurance that we will be
successful with our efforts to establish any revenue.  In order to
pursue our existing operational plan, we are dependent upon the
continuing financial support of creditors and stockholders until such
time when we are successful in raising equity capital to finance the
operations and capital requirements of the Company or until such time
that we can generate our own revenue from our various divisions.

RISK FACTORS

Dependence upon external financing

It is imperative that we raise additional capital to complete our
operational plan to promote and commercialize our newly acquired
business combinations and activities. We will also require funds to
sustain our business operations if we are not successful in earning
revenues from our various divisions. We estimate that we would require
additional funding of $250,000 to pursue our business strategy. If we
are unable to obtain equity financing upon terms that our management
deems sufficiently favorable, or at all, it would have a material
adverse impact upon our ability to expand our current operational
plan. Any sale of share capital will result in dilution to existing
shareholders.

To date, we have not generated any revenues from operations.  The
success of our business depends on our ability to develop our dental
abutment technology. The exact amount of our current and future
capital requirements will depend on numerous factors, some of which
are not within our control, including the progress of our research
and development efforts, the costs of testing and manufacturing
products, and changes in governmental regulation.  Our ability to
raise additional financing depends on many factors beyond our control,
including the state of capital markets, the market price of our
common stock and the development or prospects for development of
competitive technology by others.  The necessary additional financing
may not be available to us or may be available only on terms that
would result in further dilution to the current owners of our Common
Stock.  If we are unable to raise additional funds when we need them,
we may have to curtail or discontinue our operations, in which case
you could lose the entire amount of you investment in the Company.

Dependence on key management and personnel

Our success is highly dependent upon the continued services of Mr.
Donald Walker, our President and Mr. Robert Rosner our VP Investor
Relations & Director of Regulatory Affairs.  If any of the foregoing
persons were to leave us, it could have a materially adverse effect
upon our business and operations.  We anticipate entering into
employment contracts with the foregoing individuals, but can provide
no assurance that we will come to terms for such employment agreements.

Our business also requires additional staff in all areas to success-
fully bring our technology to market. Our success depends on our ability
to attract and retain technical and management personnel with expertise
and experience in the dental device business and in the healthcare
business. The competition for qualified personnel in the dental device
industry and healthcare industry is intense and we may not be successful
in hiring or retaining the requisite personnel.  If we are unable to
attract and retain qualified technical and management personnel, we
will suffer diminished chances of future success.

Risk of Our Intellectual Property and Protection

On June 26, 2002, the Company's wholly owned subsidiary, MBG USA,
finalized a U.S. court directed legal settlement with one infringing
company that resulted in a fully paid up license fee and cash
settlement for MBG USA of $280,000.

It is the Company's intention over the next several months, to
develop and implement a legal strategy to help extract financial
compensation from certain other entities which have also chosen to
willfully infringe on the Company's Patents by commercializing similar
technologies. In addition, the Company intends to arrange with other
companies to produce and/or license the production of dental implants
based on the patents held by ADT. The Company's ability to pursue
these opportunities is in large part contingent upon our obtaining
additional capital to assist in the associated legal and operational
infrastructure costs. If the company is unable to raise such additional
funds it is possible that the company business could potentially fail.
Furthermore, even though the company's patents have been upheld as
valid and enforceable by a US Nevada District Court Judge, there can
be no assurances that subsequent legal proceedings will result in
similar awards and or financial settlements with other potential
defendants.

Our success depends, in part, on our ability to secure and maintain
Patent protection, to preserve our trade secrets, and to operate
without infringing on the patents of third parties. Third parties may
challenge, invalidate, or circumvent our patent applications in the
future. Competitors, many of which have significantly more resources
than we have and have made substantial investments in competing
technologies, may apply for and obtain patents that will prevent, limit,
or interfere with our ability to make, use, or sell our products either
in the United States or abroad.

In the United States, patent applications are secret until patents
issue, and in foreign countries, patent applications are secret for
a time after filing. Publications of discoveries tend to significantly
lag the actual discoveries and the filing of related patent applications.
Third parties may have already filed applications for patents for
products or processes that will make our products obsolete or will
limit our patents or invalidate our patent applications.

We are in our early stages of development and face a risk of business
failure.

We are in our early stages of development. We have no way to evaluate
the likelihood that we will be able to operate the business successfully.
The likelihood of success must be considered in light of the problems,
expenses, difficulties, complications and delays encountered in
connection with the technology industry. We recognize that if we are
unable to generate significant revenues from our various divisions, we
will not be able to earn profits or continue operations. There is only
a limited history upon which to base any assumption as to the likelihood
that we will prove successful, and we can provide investors with no
assurance that we will generate any additional operating revenues or
ever achieve profitable operations from our current business initiatives.
If we are unsuccessful in addressing these risks, our business will most
likely fail.

If there is a market for our common stock, our stock price may be
volatile

If there's a market for our common stock, we anticipate that the market
price of our common stock will be subject to wide fluctuations in
response to several factors, including:

1)   actual or anticipated variations in our results of operations;
2)   our ability or inability to generate new revenues;
3)   increased competition; and
4)   conditions and trends in the technology industry.


ITEM 7.  FINANCIAL STATEMENTS

Our financial statements are stated in United States dollars and are
prepared in accordance with the United States generally accepted
accounting principles. The audited financials statements ended September
30, 2004, the independent auditor's report, and the notes to the
financial statements are attached as Exhibit 13 with this filing.


Index  to  Financial  Statements:

1.     Independent  Auditors'  Report;

2.     Audited  Consolidated  Financial  Statements

     a.   Consolidated Balance Sheets as at September 30, 2004 and 2003;

     b.   Consolidated Statements of Changes in Capital Deficit for the
          period from March 14, 2001 (inception) to September 30, 2004;

     c.   Consolidated Statements of Operations for the years ended
          September 30, 2004 and 2003 and for the cumulative period from
          March 14, 2001 (inception) to  September 30, 2004;

d. Statements of Cash Flows for the years ended September 30, 2004
and 2003 and for the cumulative period from March 14, 2001
(inception) to  September 30, 2004;

     e.   Summary  of  Significant  Accounting  Policies

     f.   Notes  to  Financial  Statements.

ITEM 8.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
         AND FINANCIAL DISCLOSURE

None

ITEM 8A.  CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. Our chief
executive officer and our principal financial officer, after
evaluating the effectiveness of the Company's "disclosure controls
and procedures" (as defined in the Securities Exchange Act of 1934
Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by
this quarterly report (the "Evaluation Date"), has concluded that as
of the Evaluation Date, our disclosure controls and procedures were
adequate and designed to ensure that material information relating to
us and our consolidated subsidiaries would be made known to him by
others within those entities.

(b) Changes in internal control over financial reporting. There were
no significant changes in our internal control over financial
reporting during our most recent fiscal quarter that materially
affected, or is reasonably likely to materially affect, our internal
control over financial reporting.

PART III

ITEM 9.  DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL
         PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

Board of Director Members:

As of September 30, 2004 the Company had the following two (2) board of
Director members.

Mr. Donald G. Walker - Director
Mr. Robert Rosner -Director

On October 31, 2003 Mr. Douglas P Johnson joined the Company's Board of
Directors and resigned February 26, 2004.

Effective February 28, 2004, Dr. Andrew Willoughby was removed as the
Chief Executive Officer and removed as director March 25, 2004.

The following table sets forth the name, age and position of each
director and executive officer of Cimbix as at September 30, 2004:

<TABLE>
<CAPTION>
Name                    Age  Position
--------------------------------------------------------------------

                      <c>  <c>
Donald G Walker           57   President, Chief Executive Officer, Director
Robert Rosner             40   Vice President of Regulatory Affairs and
                               Compliance, Corporate Secretary and Director

</table>

Set forth below is a brief description of the background and business
experience of each of our executive officers and directors for the
past five years.

Mr. Donald G. Walker B.Com, LLB, M.B.A., - President, Chief Executive
Officer, General Corporate Council & Director.  Mr. Walker is an
active member of the California Bar and has been a lawyer in private
practice for over 30 years as both a partner and sole practitioner,
representing clients in such diverse areas as general corporate law,
personal and corporate tax planning, real estate, immigration,
insurance coverage litigation and general litigation.  Mr.
Walker has acted for numerous corporate executives of public
companies in respect to various issues of fiduciary and ethical
duties.  Between 1975 and 1981 Mr. Walker was responsible
for incorporating well over four hundred (400) new privately held
companies, as well as designing and implementing their various
capital share structures and requirements for corporate governance.
As an entrepreneur, Mr. Walker also has considerable experience with
successfully developing and managing numerous privately held start-
up enterprises including the development of numerous real estate
projects in both Canada and the U.S., recently completing the
development of the Mexican Consulate in San Jose, Ca.  Mr. Walker
was an owner of a private telemarketing company based in San
Diego, California which operated a 135 employee call-center which
markets self improvement courses and other products.  As the
founder of D.G. Walker & Associates, Attorney's-at-Law, Walker also
currently represents numerous Canadian and Chinese investors as part
of a specialized immigration practice.  Walker received both his
B.Com and LLB from the University of Alberta, Canada and his M.B.A.
from the University of California.  As a member of the Company's
Board of Directors as well as its general corporate counsel Walker
brings to bear proven legal expertise, an extensive familiarity with
US corporate governance issues, as well as a strong working
knowledge of how to integrate and manage the corporate sales
function with various potential licensing strategies.

Mr. Robert Rosner - Vice President Regulatory Affairs & Compliance:
Mr. Rosner serves as the Company's Vice President of Regulatory
Affairs and Compliance, Corporate Secretary and as a member of
Cimbix's board of directors.   Mr. Rosner was appointed to the
Company's board of directors and as Vice President of Regulatory
Affairs and Compliance and Corporate Secretary on August 15, 2003.
For the past two years Mr. Rosner has also functioned as a VP of
Investor Relations and Business Development for MBG USA.  From
September 1999 till September 2003, Mr. Rosner was also the President
of First Cypress Technologies Inc., a junior mining company listed on
the NASD-OTC Bulletin Board.  He has been the owner and the president
of Rosner Communications Inc. from July 1985 to April 2004. Rosner
Communications Inc. provides consulting services to public companies.
Mr. Rosner has been the president and a director of Moreno Ventures
Inc., a company listed on the Canadian Venture Exchange, from July 1994
to December 2002.  Mr. Rosner has been the former president and a Current
director of Fortuna Ventures Inc., a company listed on the Canadian
Venture Exchange, since June 1996.  Mr. Rosner has been the president
and a director of Superior Networks, Inc., a company listed on the
NASD-OTC Bulletin Board, from February 2002 to September 2002.  As MBG
USA's VP Investor Relations and Business Development Mr. Rosner
currently works and operates out of the Company's California offices.

TERM OF OFFICE

Our  officers are  appointed for a one-year term to hold office
until the next annual  general  meeting  of  our  shareholders  or
until removed from office in accordance  with  our  bylaws.  Our
officers  are  appointed  by  our  board of directors  and  hold
office  until  removed  by  the  board.

SECTION  16(a)  BENEFICIAL OWNERSHIP REPORTING COMPLIANCE


ITEM 10. EXECUTIVE OFFICERS AND DIRECTORS COMPENSATION

The table below summarizes all compensation awarded to, earned by,
or paid to our executive officers by any person for all services
rendered in all capacities to us for the fiscal year ended September
30, 2004.  No officers or directors received annual compensation in
excess of $100,000 during the last two complete fiscal years.

                     Fiscal Year 2004 Officers Annual Compensation Table
<table>
<caption>
                           Annual  Compensation         Long  Term  Compensation
                           --------------------         ------------------------
                                                Other                                   All
                                                Annual                                  Other
                                                Compen  Restricted                      Com-
                                                sation  Stock    Options/  LTIP         pen-
Name            Title     Year  Salary   Bonus  (stock) Awarded  SARs (#)  payouts ($)  sation
------------  ----------  ----  -------  -----  ------  -------  --------  -----------  ------
<S>          <C>          <C>  <C>        <C>    <C>     <C>      <C>       <C>          <C>

Dr. Andrew   Chairman (1) 2004   $25,000   0       0      0         0        0            0
Willoughby   Director

Donald       President    2004   $33,750   0       0      0         0        0            0
Walker       & CEO,
             Director

Robert       Corporate    2004   $45,000   0       0      0         0        0            0
Rosner       Secretary,
             VP Reg.
             Affairs,
       	 Director

</table>

As of September 30, 2004, none of the executive officers had any
sort of binding employment contracts with the Company.  However,
in addition to being a Vice President of Regulatory Affairs for
the Company, Mr. Robert Rosner earned for the 2004 fiscal
year an annual base salary of $60,000 as Vice President of Investor
Relations and Business Development for the Company's wholly owned
subsidiary, MBG USA. In this capacity Mr. Rosner is responsible
for managing the expansion of MBG USA's US sales, marketing and
investor relations offices in Los Angeles, California.

Additionally, Donald Walker earned $22,500 as President of the
Company's wholly owned subsidiary, MBG USA. In this capacity, Mr.Walker
is responsible for overseeing the day-to-day operations of MBG USA.

As of September 30, 2004 the Company has not adopt any compensation
committee or compensation policies. See "Certain Relationships and
Related Transactions." Other than as detailed above, the Company has
no stock option, retirement, incentive, defined benefit, actuarial,
pension or profit-sharing programs for the benefit of directors,
officers or other employees, but the Board of Directors may recommend
adoption of one or more such programs in the future.

ITEM 11. SECURTIY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
         MANAGEMENT

The following table sets forth, as of September 30, 2004, Cimbix's
outstanding common stock owned of record of all Executive Officers and
Directors as a group. Each person has sole voting and investment
power with respect to the shares shown.

As of September 30, 2004 the total number of issued and outstanding
common shares in the Company was 42,967,100.  5% of which equals
2,148,355 shares.

<TABLE>
<CAPTION>
                                                       Amount of         Percent
                           Name and address            beneficial        of
Title of Class             of beneficial owner         ownership         class
                           -----------------------------------------------------
<S>                        <C>                          <C>               <C>
Common Stock                Donald Walker                15,075,000           35.08%
                            Chairman, President, CEO
                            99 Elm Ave
                            Larkspur, California
                            94939

Common Stock                Robert Rosner                15,250,000           35.49%
                            Director, Secretary
                            #134, 9663 Santa Monica Blvd
                            Beverly Hills, California
                            90210


                                                         -------------       -------
                                                         30,325,000           70.57%
</table>

Total combined share position of all executive officers
and directors as a group consists of 2 persons

The following table sets forth, as of September 30, 2004, Cimbix's
outstanding common stock owned of record or beneficially by each
person who owned of record, or was known by Cimbix to own beneficially,
more than 5% of its common stock. Each person has sole voting and
investment power with respect to the shares shown.


      TABLE OF SHAREHOLDERS WITH MORE THAN 5% HOLDINGS OF CIMBIX
<TABLE>
<CAPTION>
                                                       Amount of         Percent
                           Name and address            beneficial        of
Title of Class             of beneficial owner         ownership         class
                           -----------------------------------------------------
<S>                        <C>                          <C>               <C>
Common Stock                Donald Walker                15,075,000           35.08%
                            Chairman, President, CEO
                            99 Elm Ave
                            Larkspur, California
                            94939

Common Stock                Robert Rosner                15,250,000           35.49%
                            Director, Secretary
                            #134, 9663 Santa Monica Blvd
                            Beverly Hills, California
                            90210

Common Stock                Edwin Lao                     7,500,000           17.46%
                            former director and officer
                            Shareholder


                                                         -------------       -------
                                                         37,825,000           88.03%
</table>



Under the rules of the Securities and Exchange Commission, a person
(or group of persons) is deemed to be a "beneficial owner" of a
security if he or she, directly or indirectly, has or shares the
power to vote or to direct the voting of such security, or the power
to dispose of or to direct the disposition of such security.
Accordingly, more than one person may be deemed to be a beneficial
owner of the same security.  A person is also deemed to be a
beneficial owner of any security, which that person has the right to
acquire within 60 days, such as options or warrants to purchase the
common stock of Cimbix.  There were no rights outstanding as of
September 30, 2004 entitling owners to acquire our common stock within
60 days.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

No director, executive officer or nominee for election as a director
of the Company and no owner of five percent or more of Cimbix's
outstanding shares or any member of their immediate family has
entered into or proposed any transaction in which the amount involved
exceeds $60,000 except as noted above.

ITEM 13.  EXHIBITS AND REPORTS ON FORM 8-K

(a)     Exhibits  and  Index  of  Exhibits

<table>
  Exhibit
  Number                         Description of Exhibit
--------------     -------------------------------------------------

                <c>
  3.3                Amendment of Articles of Incorporation (1)
 10.1                Share Exchange Agreement between the Company and
                     the Millenium Business Group USA, Inc. (2)
 13.2                Audited Consolidated Financials Statements for
                     the year ended September 30, 2004 (3)
 16.1                Change of Certifying Accountant (4)
 31.1                Certification 302, CEO (3)
 32.1                Certification 906, CEO (3)
 --------------     -------------------------------------------------
</table>
(1)     Previously  filed  with  the  Securities  and  Exchange
Commission as an exhibit  to  the  Form 8-K dated  June 14, 2004.
(2)     Previously  filed  with  the  Securities  and  Exchange
Commission as an exhibit  to  the  Form 8-K dated April 9, 2003 and
August 19, 2003.
(3)     Attached as exhibit to the current Form 10-KSB
(4)     Previously  filed  with  the  Securities  and  Exchange
Commission as an exhibit  to  the  Form 8-K dated July 2, 2003.


(b)     Reports  on  Form  8-K.

On July 2, 2003, we reported with the US Securities and Exchange
Commission the dismissal of Manning Elliott, Chartered Accountants
and the appointment of Morgan & Company, Chartered Accountants as our
principal independent accountant.

On April 9 and August 19, 2003, we reported with the US Securities
and  Exchange Commission that we had entered into a Share Exchange
Agreement between the shareholders of the Millenium Business Group
USA, Inc. and the Company.  The subsequent filing reported the
audited financial information of the Millenium Business Group USA,
Inc., a wholly owned subsidiary.  The Millenium Business Group USA,
Inc. provided an audited financials as well as a proforma unaudited
financials as of September 30, 2002, as if the transaction was
completed and all obligations had been assumed as of September 30,
2002.

On August 26, 2003,  we  reported with the US Securities and
Exchange Commission that we had changed the Company's name from
Corporate Development and Innovation, Inc. to Cimbix Corporation.

On November 26, 2003, we reported with the US Securities and Exchange
Commission that we appointed a new President and director, Mr.
Douglas P Johnson.

On March 26, 2004, we reported with the US Securities and Exchange
Commission that we accepted Mr. Douglas P. Johnson's resignation; that
Mr. Andrew Willoughby was removed as Chief Executive Officer; we
re-affirmed the Company's bylaws; issuance of shares to Mr. Donald
Walker and Mr. Robert Rosner; and proposed termination of the share
exchange agreement between the Company and Millenium Business Group
USA Inc.

On June 14, 2004, we reported with the US Securities and Exchange
Commission that Mr. Andrew Willoughby was removed as director; that
current management appropriately established the designation of the
voting preferred shares of the Company to be one (1) vote each; and
that Mr. Robert Rosner and Mr. Donald Walker did not accept the
issuance of shares disclosed on March 26, 2004.

On September 24, 2004, we reported with the US Securities and Exchange
Commission that as a result of restructuring and reorganization of
The Company, the board of directors and major shareholders approved a
Reverse stock split of two hundred shares to one share of the issued
And outstanding shares of the common stock of the Company.

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

AUDIT FEES

The aggregate fees billed for each of the fiscal years ended
September 30, 2004 and 2003 for professional services rendered by the
principal accountant for the audit of Cimbix's annual financial
statements and review of the financial statements included in the
registrant's Form 10-QSB or services that are normally provided by
the accountant in connection with statutory and regulatory filings or
engagements for those fiscal years were estimated at $7,000 and
$6,800 respectively.

AUDIT RELATED FEES

None

TAX FEES

None

ALL OTHER FEES

None


<PAGE>
                                   SIGNATURES



In  accordance  with  Section  13  or  15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


CIMBIX CORPORATION


By:  /s/  DONALD WALKER
     ___________________________________
     DONALD WALKER, President, CEO and Director
     Date:     February 11, 2005


In accordance with the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.


By:  /s/ DONALD WALKER
     ___________________________________
     DONALD WALKER, Principal Executive Officer
     Principal Financial Officer
     Chief Executive Officer and Director
     Date:     February 11, 2005